Shares in the biggest listed healthcare services operators all plummeted in mid March as the COVID pandemic spread rapidly. As our infographic illustrates, only around half of these have substantially recovered their value.
NMC acting CEO Michael Davis speaks publicly for the first time about the future of under-fire NMC Health. In this exclusive interview, we ask about a possible sale of all or part of the business, and whether and how NMC might recover from its present position.
Analyst forecasts suggest that healthcare sector valuations have been largely unaffected by the crisis, with EMEA hospitals and medtech stocks now being more expensive than before the Covid outbreak, both on an EBITDA and PE multiples basis.
Now that Steward Health Care has been bought by its doctors, what future does it face in Malta where the deal it inherited to run almost half the country’s public hospitals had attracted scrutiny? HBI talks exclusively to Dr Armin Ernst, CEO and President of Steward Health Care International.
How many doctors are using Skype and other vanilla, publicly available platforms and how many are adopting built for purpose telehealth solutions? This Danish data gives some indication of the likely split between the only officially recommended solution and what are likely to be vanilla, publicly available platforms. The Danish doctors union has historically been […]
Healthcare systems are often seen as ponderous behemoths, set on a particular course and slow to adapt and change direction. The sense of urgency engendered by the COVID pandemic has shown that, when they have to, they can adapt, adopt new technology, and innovate quickly to save lives.
Belgian dentistry is booming again, with attendance exceeding pre-COVID levels, but even this revving up won't make up for lost revenue after months of closure. HBI speaks to an operator source to find out more.
Thanks to Covid, Aster DM, the GCC to India clinic, hospital and pharmacy chain, saw a 25% drop in revenue across both geographies in April. May and June have seen improvements with a return to normal expected in the autumn, providing there is no second wave. We look in detail at the impact of Covid in March to June and report full year results to March 2020.
UK lab group Viapath has been nationalised, after Guy's and St Thomas' and King's College Hospital NHS Foundation Trusts bought out its private sector partner Serco following the loss of a £2.25bn outsourcing contract in which Synlab remains the preferred bidder. Could Synlab's expected success be the first of a slew of new outsourcing contracts for big lab platforms? HBI talks to a consultant to find out more.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.